Investors' focus could, however, shift back onto the possible market impacts of GLP-1 agonists in 2025, particularly as a result of a major expansion of current supplies after Novo Nordisk was given a ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 496.78% and ...

The president-elect is set to appear with SoftBank Group CEO Masayoshi Son at Mar-a-Lago on Monday. The industrial conglomerate said its board continued to explore strategic alternatives and plans to ...

Mike Plante struggled with his weight for years, but within six months of starting with the injection drug semaglutide, a ...

The monthslong battle over the future of the weight-loss drug industry is headed for a climax this week, when the Food and ...

On the other hand, the nature of its industry means that there will often be solid new reasons to be a bit more cautious ...

Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...

Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...

NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...

The U.S. obesity rate declined for the first time in a decade last year, coinciding with the rise of GLP-1 weight-loss ...

A few years ago, West Virginia, which has the highest obesity rate in the nation, quietly began a small and unusual pilot ...

These weight loss drugs are expensive out of pocket, though. Even with insurance, high co-pays can also limit who has access ...